Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Valneva SE made materially false and/or misleading statements and/or failed to disclose that: On August 25, 2025, before the market opened, Valneva announced that the FDA suspended the license for its chikungunya vaccine IXCHIQ due to new reports of serious adverse events consistent with chikungunya-like illness. The suspension is effective immediately and Valneva is required to stop the shipping and selling of its IXCHIQ vaccine in the U.S. Following this news, VALN’s stock price fell over 22% to open at $9.12 per share.
In order to be eligible to join the VALN class action lawsuit, you must have incurred a loss on shares of Valneva SE purchased during the class period listed above.
TOP
